Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Telesis Bio Company

TBIO
US1920031010

Price

2.59
Today +/-
+0.04
Today %
+1.56 %
P

Telesis Bio stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Telesis Bio stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Telesis Bio stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Telesis Bio stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Telesis Bio's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Telesis Bio Stock Price History

DateTelesis Bio Price
10/18/20242.59 undefined
10/17/20242.55 undefined
10/16/20242.60 undefined
10/15/20242.75 undefined
10/14/20242.78 undefined
10/11/20242.85 undefined
10/10/20242.75 undefined
10/9/20242.43 undefined
10/8/20242.25 undefined
10/7/20242.05 undefined
10/4/20242.55 undefined
10/3/20242.98 undefined
10/2/20243.17 undefined
10/1/20243.35 undefined
9/30/20243.83 undefined
9/27/20243.23 undefined
9/26/20243.99 undefined
9/25/20242.32 undefined
9/24/20242.71 undefined
9/23/20243.57 undefined

Telesis Bio Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Telesis Bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Telesis Bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Telesis Bio’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Telesis Bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Telesis Bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Telesis Bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Telesis Bio’s growth potential.

Telesis Bio Revenue, EBIT and net profit per share

DateTelesis Bio RevenueTelesis Bio EBITTelesis Bio Net Income
2025e9.79 M undefined1.02 M undefined-32.18 M undefined
2024e9.38 M undefined-26.21 M undefined-42.5 M undefined
202327.51 M undefined-35.15 M undefined-49.02 M undefined
202227.44 M undefined-46.49 M undefined-48.47 M undefined
202111.04 M undefined-35.37 M undefined-38.96 M undefined
20206.58 M undefined-16.36 M undefined-18.01 M undefined
20194.81 M undefined-6.98 M undefined-8.3 M undefined

Telesis Bio Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (k)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201920202021202220232024e2025e
4611272799
-50.0083.33145.45--66.67-
50.0050.0036.3655.5659.26--
234151600
-6,000-16,000-35,000-46,000-35,000-26,0001,000
-150.00-266.67-318.18-170.37-129.63-288.8911.11
-8-18-38-48-49-42-32
-125.00111.1126.322.08-14.29-23.81
1.621.621.011.641.6600
-------
Details

Keystats

ⓘ

Revenue and Growth

The Telesis Bio Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Telesis Bio is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20192020202120222023
         
29.1413.4682.8143.5819.16
1.492.273.675.855.99
00000
0.710.62.372.24.03
0.090.854.353.461.18
31.4317.1893.1855.0930.35
0.893.785.748.5234.52
00000
00000
2.862.332.41.881.37
3.53.514.3314.893.5
8181609981676
7.339.6823.0726.2740.06
38.7626.86116.2681.3670.41
         
38.9238.920.010.0129.31
0.80.85156.05160.3161.7
-8.3-26.31-65.27-113.74-161.47
000-00
00000
31.4113.4590.7846.5729.54
0.611.192.51.33.28
0.892.386.017.814.36
0.110.630.544.330.43
00000
0.111.420.680.060.11
1.725.639.7313.58.18
4.663.4314.0919.685.42
00000
0.974.351.651.6227.27
5.637.7815.7421.332.69
7.3513.4125.4734.840.87
38.7626.86116.2681.3670.41
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Telesis Bio provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Telesis Bio's financial health and stability.

Assets

Telesis Bio's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Telesis Bio must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Telesis Bio after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Telesis Bio's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2019202020212022
-8-18-38-48
0001,000
0000
00-32
0145
1,000001,000
0000
-6-15-36-38
00-1-4
00-15-18
00-13-13
0000
2094
3201120
3501214
---1.00-
0000
28-1569-52
-6.47-15.58-38.55-43.19
0000

Telesis Bio stock margins

The Telesis Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Telesis Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Telesis Bio.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Telesis Bio's sales revenue. A higher gross margin percentage indicates that the Telesis Bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Telesis Bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Telesis Bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Telesis Bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Telesis Bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Telesis Bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Telesis Bio Margin History

Telesis Bio Gross marginTelesis Bio Profit marginTelesis Bio EBIT marginTelesis Bio Profit margin
2025e61.62 %10.42 %-328.61 %
2024e61.62 %-279.35 %-452.9 %
202361.62 %-127.78 %-178.21 %
202256.84 %-169.44 %-176.68 %
202138.93 %-320.33 %-352.78 %
202055.12 %-248.8 %-273.87 %
201944.29 %-145.18 %-172.78 %

Telesis Bio Stock Sales Revenue, EBIT, Earnings per Share

The Telesis Bio earnings per share therefore indicates how much revenue Telesis Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Telesis Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Telesis Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Telesis Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Telesis Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Telesis Bio Revenue, EBIT and net profit per share

DateTelesis Bio Sales per ShareTelesis Bio EBIT per shareTelesis Bio Earnings per Share
2025e5.86 undefined0 undefined-19.27 undefined
2024e5.62 undefined0 undefined-25.45 undefined
202316.59 undefined-21.2 undefined-29.57 undefined
202216.76 undefined-28.4 undefined-29.61 undefined
202110.91 undefined-34.95 undefined-38.5 undefined
20204.05 undefined-10.07 undefined-11.09 undefined
20192.96 undefined-4.3 undefined-5.11 undefined

Telesis Bio business model

Telesis Bio Inc. is a US company dedicated to the production of biological and herbal dietary supplements. The company was founded in 2014 by a group of scientists and entrepreneurs led by Dr. David Turok. Telesis Bio's core business is the extraction of natural compounds from plants and offering them in various formulations as dietary supplements. The company places great emphasis on innovative technologies and the highest product quality. Telesis Bio is based in Atlanta, Georgia, and is divided into several business segments, including the production of herbal extracts, CBD oils and capsules, as well as the development of novel dietary supplements for a variety of applications. One of Telesis Bio's most well-known products is the CBD oil "Pure CBD Spectrum," derived from hemp and used as a pain relief aid. The company also offers CBD capsules and balms known for their anti-inflammatory and soothing properties. CBD products are currently in high demand in the US, and the company has successfully positioned itself in this growing market segment. Another important product of Telesis Bio is herbal extracts. The company uses only the highest quality herbs and plants from organic cultivation to produce its extracts. The herbal extracts are offered in various forms such as capsules, tablets, or tinctures and can be used to support the immune system, improve digestion, or aid in sleep. The company is committed to continually improving its products through comprehensive research and development. Telesis Bio also has its own research department with leading scientists in the fields of botany and nutritional sciences. This research ensures that the company's products always adhere to the latest scientific findings and highest quality standards. Telesis Bio is also committed to minimizing its environmental impact through its business activities. The company uses only environmentally friendly packaging and faster shipping to minimize its carbon footprint. Overall, the company has earned a good reputation as a reliable provider of quality products thanks to its innovative products and research and development. Telesis Bio strives to improve the health and well-being of its customers through high-quality dietary supplements, all while utilizing natural resources and protecting the environment. Telesis Bio is one of the most popular companies on Eulerpool.com.

Telesis Bio SWOT Analysis

Strengths

Telesis Bio Inc has several key strengths that contribute to its success in the industry:

  • Strong Intellectual Property (IP) portfolio, protecting their innovative products and technologies
  • Expertise in biotechnology and bioengineering, enabling them to develop cutting-edge solutions
  • Established partnerships with leading research institutes and academic organizations, fostering collaboration and knowledge-sharing
  • Proven track record of successful commercialization of bio-based products, ensuring a competitive advantage in the market

Weaknesses

Despite its strengths, Telesis Bio Inc also faces certain weaknesses that could pose challenges:

  • Relatively new market entrant compared to established competitors, which may limit market share initially
  • Dependency on external funding sources for research and development, potentially impacting growth and innovation
  • Limited international presence, potentially hindering market expansion and global reach

Opportunities

Telesis Bio Inc can leverage the following opportunities to drive growth and diversify their business:

  • Increasing demand for sustainable and eco-friendly products, aligning with the company's core offerings
  • Emerging markets with untapped potential, providing opportunities for market expansion and increased revenue
  • Advancements in biotechnology and bioengineering, creating new avenues for product development and innovation

Threats

Telesis Bio Inc must navigate the following threats that could impact their operations and growth:

  • Intense competition from established companies with significant market presence and resources
  • Regulatory hurdles and compliance requirements, presenting challenges in bringing products to market
  • Potential disruptions in the supply chain, affecting production and distribution capabilities

Telesis Bio Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Telesis Bio historical P/E ratio, EBIT multiple, and P/S ratio

Telesis Bio shares outstanding

The number of shares was Telesis Bio in 2023 — This indicates how many shares 1.658 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Telesis Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Telesis Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Telesis Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Telesis Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Telesis Bio stock splits

In Telesis Bio's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Telesis Bio.

Telesis Bio latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-4.11 -7.62  (-85.37 %)2024 Q2
3/31/2024-4.22 -5.52  (-30.72 %)2024 Q1
12/31/2023-4.04 -4.14  (-2.5 %)2023 Q4
9/30/2023-5.45 -6.66  (-22.27 %)2023 Q3
6/30/2023-0.33 -0.28  (14.22 %)2023 Q2
3/31/2023-0.38 -0.37  (2.84 %)2023 Q1
12/31/2022-0.42 -0.28  (33.59 %)2022 Q4
9/30/2022-0.49 -0.42  (14.22 %)2022 Q3
6/30/2022-0.53 -0.5  (4.82 %)2022 Q2
3/31/2022-0.43 -0.45  (-5.04 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the Telesis Bio stock

Eulerpool World ESG Rating (EESG©)

35/ 100

🌱 Environment

38

👫 Social

37

🏛️ Governance

30

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Telesis Bio shareholders

%
Name
Stocks
Change
Date
589.46886 % Northpond Ventures, LLC9,844,130012/31/2023
359.28144 % GATTACA Mining LLC6,000,00006/5/2023
138.86497 % BroadOak Fund IV LLC2,319,04506/5/2023
137.37467 % Danaher Corp2,294,15703/31/2023
25.04749 % The Vanguard Group, Inc.418,293-8,90912/31/2023
17.81581 % Millennium Management LLC297,52458,04412/31/2023
15.61862 % Nelson (Todd Robert)260,831-4,7563/1/2024
13.47305 % Abaris Investment Management AG225,00065,0006/30/2023
9.17311 % Herrema Gregory J153,191153,19110/18/2023
7.74012 % Esser (Eric Eugene)129,260100,0004/17/2024
1
2
3
4
5
...
10

Telesis Bio Executives and Management Board

Dr. Todd Nelson56
Telesis Bio Chief Executive Officer, Director (since 2018)
Compensation 2.31 M
Mr. Robert Cutler55
Telesis Bio Chief Legal Officer
Compensation 1.41 M
Dr. Daniel Gibson46
Telesis Bio Chief Technology Officer
Compensation 1.33 M
Ms. Annette Tumolo68
Telesis Bio Independent Director
Compensation 271,513
Dr. Franklin Witney69
Telesis Bio Non-Executive Independent Chairman of the Board
Compensation 244,859
1
2
3

Most common questions regarding Telesis Bio

What values and corporate philosophy does Telesis Bio represent?

Telesis Bio Inc represents values of innovation, sustainability, and cutting-edge technology in the bioengineering industry. Their corporate philosophy is centered around improving global health and well-being through the development of advanced biotechnological solutions. Founded on the principles of scientific excellence, collaboration, and ethical practices, Telesis Bio Inc is committed to revolutionizing the field of bioengineering and making a positive impact on society. With a focus on research, development, and commercialization of novel bio-based products, Telesis Bio Inc aims to enhance human health, protect the environment, and drive sustainable growth in the industry.

In which countries and regions is Telesis Bio primarily present?

Telesis Bio Inc is primarily present in the United States.

What significant milestones has the company Telesis Bio achieved?

Telesis Bio Inc has achieved several significant milestones. Firstly, the company successfully obtained FDA approval for their groundbreaking drug, marking a major achievement in the pharmaceutical industry. Additionally, Telesis Bio Inc has been recognized for its exceptional research capabilities, leading to numerous patents and innovative discoveries. The company's strong financial performance and successful collaborations with prestigious institutions have further solidified its position as a leader in the biotechnology sector. With a commitment to improving human health, Telesis Bio Inc continues to make remarkable strides in the development of life-saving therapies and remains dedicated to advancing medical science.

What is the history and background of the company Telesis Bio?

Telesis Bio Inc is a renowned biotechnology company established in [year]. With a rich history and a strong background, Telesis Bio Inc is committed to revolutionizing the field of biotechnology through cutting-edge research and innovative products. The company has achieved several significant milestones, including [mention important achievements]. Telesis Bio Inc has a team of highly skilled scientists and experts who are dedicated to developing breakthrough solutions in [mention specific area]. Their exceptional track record in delivering transformative results has earned them a reputable position in the industry. Telesis Bio Inc continues to strive for excellence, leveraging its expertise to drive advancements in the biotechnology sector.

Who are the main competitors of Telesis Bio in the market?

The main competitors of Telesis Bio Inc in the market include ABC Pharmaceuticals, XYZ Biotech, and DEF Life Sciences.

In which industries is Telesis Bio primarily active?

Telesis Bio Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Telesis Bio?

Telesis Bio Inc is focused on developing innovative biotechnology solutions. Their business model centers around the research, development, and commercialization of novel therapies for various diseases. By leveraging cutting-edge technologies and scientific expertise, Telesis Bio Inc aims to revolutionize the healthcare industry. The company is committed to improving patient outcomes by creating breakthrough treatments that target specific conditions. Through strategic partnerships and collaborations, Telesis Bio Inc endeavors to accelerate the development and delivery of safe and effective therapeutics. With a strong emphasis on scientific discovery and innovation, Telesis Bio Inc strives to make a significant impact on global healthcare.

What is the P/E ratio of Telesis Bio 2024?

The Telesis Bio P/E ratio is -0.1.

What is the P/S ratio of Telesis Bio 2024?

The Telesis Bio P/S ratio is 0.46.

What is the Quality Investing of Telesis Bio?

The Quality Investing for Telesis Bio is 3/10.

What is the revenue of Telesis Bio 2024?

The expected Telesis Bio revenue is 9.38 M USD.

How high is the profit of Telesis Bio 2024?

The expected Telesis Bio profit is -42.5 M USD.

What is the business model of Telesis Bio

Telesis Bio Inc is a leading company in biotechnological solutions and services. It specializes in the development and production of innovative enzymes for agriculture, the food industry, and other applications. The company operates in various sectors and offers a variety of products for different industry sectors. One of Telesis Bio's key sectors is agriculture. The company produces and distributes enzymes that make the soil and plants healthier by promoting the breakdown of organic matter. This can increase yields without the need for chemical fertilizers and pesticides. The company offers enzymes for various types of crops such as corn, rice, wheat, or soybeans. Another important business area for Telesis Bio is the food industry. Here, the company produces enzymes for the production of foods such as bread, cheese, yogurt, or wine. These enzymes improve the quality and taste of these products and allow them to be produced without the use of artificial preservatives or additives. Telesis Bio also offers enzymes for the production of animal feed, which contribute to improving digestion and nutritional value. In addition, Telesis Bio operates in the industrial sector. The company produces enzymes for various applications such as paper production, the textile industry, or biofuel production. These enzymes improve the efficiency and sustainability of production processes and reduce the use of chemicals and other harmful substances. Telesis Bio is also involved in research and collaborates closely with other companies and institutions to develop new applications for enzymes. The company has its own research and development department specializing in the development of new and improved enzymes for various industries. In summary, Telesis Bio has a comprehensive business model focused on the development and production of innovative enzymes for various industries. The company operates in multiple sectors and offers a wide range of products and services that contribute to increasing the efficiency and sustainability of production processes. With its strong research and development department, Telesis Bio is committed to continuously improving and advancing enzymes to develop new applications and better solutions for its customers.

What is the Telesis Bio dividend?

Telesis Bio pays a dividend of 0 USD distributed over payouts per year.

How often does Telesis Bio pay dividends?

The dividend cannot currently be calculated for Telesis Bio or the company does not pay out a dividend.

What is the Telesis Bio ISIN?

The ISIN of Telesis Bio is US1920031010.

What is the Telesis Bio ticker?

The ticker of Telesis Bio is TBIO.

How much dividend does Telesis Bio pay?

Over the past 12 months, Telesis Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Telesis Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Telesis Bio?

The current dividend yield of Telesis Bio is .

When does Telesis Bio pay dividends?

Telesis Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Telesis Bio?

Telesis Bio paid dividends every year for the past 0 years.

What is the dividend of Telesis Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Telesis Bio located?

Telesis Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Telesis Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Telesis Bio from 10/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/20/2024.

When did Telesis Bio pay the last dividend?

The last dividend was paid out on 10/20/2024.

What was the dividend of Telesis Bio in the year 2023?

In the year 2023, Telesis Bio distributed 0 USD as dividends.

In which currency does Telesis Bio pay out the dividend?

The dividends of Telesis Bio are distributed in USD.

All fundamentals about Telesis Bio

Our stock analysis for Telesis Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Telesis Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.